| HOME >> BIOLOGY >> TECHNOLOGY |
VEDBAEK, Denmark, October 1 /PRNewswire-FirstCall/ --
- Announcement No. 40/2008
- To OMX Nordic Exchange Copenhagen and the Press.
Exiqon A/S today announces a grant of license to Roche Diagnostics for use of the Universal ProbeLibrary that is based on Exiqon's proprietary LNA(TM) detection technology.
Roche Diagnostics will develop its new product line for RealTime ready qPCR assays with the Universal ProbeLibrary that is based on Exiqon's proprietary LNA(TM) detection technology.
"This extension of our successful partnership with Roche allows for the application of Exiqon's LNA(TM) detection technology in the new and fast growing market for ready-to-use and customizable RealTime PCR products. We are exited to have Roche Diagnostics, who is a leader in the RealTime PCR market, embrace the LNA(TM) detection technology in their new product offering," comments Lars Kongsbak, President and CEO of Exiqon."
For additional information, reference is made to the attached press release by the parties.
The financial details of the agreement including commercial milestone payments and royalties on future product sales are not disclosed.
Exiqon retains its financial outlook for 2008 including an expected revenue of DKK 140-150 million in 2008 including both research product sales and 10 months of diagnostic sales from Oncotech's activities corresponding to full year revenues including Oncotech of DKK 150-160 million and a net loss for the year 2008 of DKK 100-115 including DKK 6 million of costs of current incentive plans, including warrants..
Exiqon maintains its long-term financial goal of profitability by 2011 with its current cash position and break even of the research products business by 2009.
About Exiqon
Exiqon is dedicated to personalizing the treatment selection for cancer
patients. Our goal is to optimize the use of existing medicine and avoid
unnecessary and non-effective treatment
'/>"/>
| SOURCE Exiqon A/S Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
2. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
5. Exiqon: Major Shareholder Announcement
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
9. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
10. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
11. eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |